Medpace Holdings, Inc.

As of June 30, 2026, Medpace Holdings, Inc. carries a market capitalization of 195.99B, placing it among publicly traded companies globally. Its enterprise value stands at 189.30B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Medpace Holdings, Inc.'s next confirmed earnings release is scheduled for February 15, 2027.

As of June 30, 2026, Medpace Holdings, Inc. has 27.91M shares outstanding.

As of June 30, 2026, Medpace Holdings, Inc. trades at a trailing price-to-earnings ratio of 23.11. The price-to-sales ratio is 4.08, and the price-to-book ratio stands at 25.86.

As of June 30, 2026, Medpace Holdings, Inc. trades at an EV/EBITDA multiple of 17.73 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.89 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 18.57 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Medpace Holdings, Inc. trades at an EV/FCF ratio of 14.48, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 189.30B versus a market cap of 195.99B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Medpace Holdings, Inc. maintains a current ratio of 0.73, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Medpace Holdings, Inc. posted a return on equity (ROE) of 162.15, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 112.48 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 27.09, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 115.48, useful for judging operating efficiency across full business cycles. The company generates approximately 7.94M in revenue per employee across its workforce of 6,125.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Medpace Holdings, Inc. recorded 1.88B in income tax expense. That works out to an effective tax rate of 17.94, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 10.46B, leaving 8.59B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on July 17, 2026, Medpace Holdings, Inc.'s stock has gained approximately 19.42% over the past 52 weeks. The 50-day moving average sits at 5,164.09, while the 200-day moving average is 4,016.23.

Over the twelve months ended June 30, 2026, Medpace Holdings, Inc. generated 48.61B in revenue and converted that into 8.59B in net income, yielding earnings per share of 297.92. EBITDA reached 10.68B, while operating income came in at 10.19B.

As of June 30, 2026, Medpace Holdings, Inc. holds 8.78B in cash and equivalents against 2.10B in total debt, resulting in a net debt position of -8.78B. Total book value stands at 7.58B, with working capital of -6.73B providing operational flexibility.

Medpace Holdings, Inc. produced 13.15B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -79.25M in capital expenditures, free cash flow totaled 13.07B - equivalent to 462.50 per share.

Over the twelve months ended June 30, 2026, Medpace Holdings, Inc. posted a gross margin of 28.76, reflecting its pricing power and cost economics. The operating margin of 20.97 and net profit margin of 17.67 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 6.46, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 2.22, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Medpace Holdings, Inc. shareholders.

As of June 30, 2026, Medpace Holdings, Inc. has an Altman Z-Score of 6.74, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.